Page 10 - Risk Evaluation News Today

The US Food and Drug Administration is evaluating reports of side effects such as hair loss and suicidal thoughts in people taking medications like Ozempic, Mounjaro and Wegovy.

The US Food and Drug Administration is evaluating reports of side effects such as hair loss and suicidal thoughts in people taking medications like Ozempic, Mounjaro and Wegovy.

ZILBRYSQ® is now commercially available by prescription in the United States and dispensed by UCBs selected exclusive specialty pharmacy PANTHERx® Rare Pharmacy.ZILBRYSQ is FDA-approved as the...

A federal judge has set a Jan. 17 hearing in Greensboro for a lawsuit challenging North Carolina’s abortion pill restrictions. The court will consider state legislative leaders’ motion to dismiss

The benefits of ketamine are clear, but so are the risksKetamine has now demonstrated clear superiority to placebo and non-inferiority to electroshock therapy in randomized trials encompassing more...

Financial statement analysis is a critical tool for individuals and businesses alike to assess the financial health and performance of a company. By examining

Cytokinetics drug aficamten met the main goal of a pivotal test in obstructive hypertrophic cardiomyopathy. If approved, the daily pill would compete against a Bristol Myers Squibb drug projected to become a blockbuster seller.

The Big Picture - On December 13, 2023, the Supreme Court announced its intention to review the August 16 ruling by the Fifth Circuit in Alliance for Hippocratic Medicine...

-- Yescarta is the First and Only Treatment in Nearly 30 Years to Demonstrate Superior Overall Survival for Patients with Relapsed/Refractory Large B-cell Lymphoma Versus Standard of Care as...

21.12.2023 - Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Yescarta (axicabtagene ciloleucel) to include the overall survival (OS) primary analysis from the landmark Phase ...